z-logo
open-access-imgOpen Access
Evaluation of the relationship between TREM‐1/TREM‐2 ratio and clinical course in COVID‐19 pneumonia
Author(s) -
Kerget Ferhan,
Kerget Buğra,
İba Yılmaz Sibel,
Kızıltunç Ahmet
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14697
Subject(s) - medicine , covid-19 , pneumonia , betacoronavirus , coronavirus infections , intensive care medicine , virology , infectious disease (medical specialty) , disease , outbreak
Abstract Objective The inflammatory/anti‐inflammatory balance has an important role in the clinical course of SARS‐CoV‐2 infection (COVID‐19), which has affected over 100 million people since it first appeared in China in December 2019. The aim of this study was to investigate the relationship between triggering receptor expressed on myeloid cells (TREM)‐1/TREM‐2 ratio and COVID‐19 severity. Methods A total of 171 individuals were included in the study: 121 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID‐19 by real‐time PCR of nasopharyngeal swab samples from December 2020 to March 2021 and a control group consisting of 50 asymptomatic health workers in our hospital who had negative real‐time PCR results during routine COVID‐19 screening. Results TREM‐1 level was significantly higher in patients with severe disease compared with the moderate and control groups ( P  = .003, P  = .001). TREM‐2 levels did not differ significantly in moderate and severe patients ( P  = .36) but were significantly higher in both patient groups compared with the control group ( P  = .001 for both). TREM‐1/TREM‐2 ratio was significantly higher in the severe patient group than in the moderate and control groups ( P  = .001 for both). In receiver operating characteristic curve analysis of TREM‐1/TREM‐2 ratio in patients with moderate and severe COVID‐19, the area under the curve was 0.723. Using a cut‐off value of 0.125 for TREM‐1/TREM‐2 ratio in the Youden index calculation, the sensitivity was 60% and specificity was 71%. Conclusion Experience with the positive effects of medical treatments to restore inflammatory balance in the course of COVID‐19 is steadily increasing. TREM‐1 and TREM‐2 have an important role in inflammation and may serve as biomarkers and therapeutic targets in the early treatment and follow‐up of COVID‐19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here